Obesity Drugs Evolve: Is the Exercise Workforce Keeping Pace?
The piece revisits how obesity treatments have evolved since 2023 and asks what those changes mean for exercise professionals. It notes that semaglutide drew widespread attention, tirzepatide was nearing obesity approval, and many other therapies were in development when the original perspective was written. The article frames the current landscape as a prompt for the exercise field to reassess its role.
Since 2023, obesity treatment has drawn growing interest as semaglutide attracted wide notice and tirzepatide approached an obesity approval, with other therapies still in development when the earlier perspective was prepared.
The exercise field is now prompted to reconsider its place in this changing landscape. ACSM’s offerings include an Obesity Care Exercise Specialist Certificate among its specialty programs.
As obesity medications become more prominent, patients, clinicians, and exercise professionals may face new questions about combining pharmacotherapy with activity support. People seeking weight management could encounter more integrated care pathways, while trainers and exercise specialists may need updated competencies. Access, affordability, and coordination could shape whether these changes broaden options or leave gaps; the exercise workforce’s response may influence how safely and effectively patients incorporate physical activity alongside treatment.